Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Queensland Health
Fish and Richardson
Chubb
QuintilesIMS
UBS
Teva
Harvard Business School
Fuji

Generated: July 18, 2018

DrugPatentWatch Database Preview

Msd Intl Company Profile

« Back to Dashboard

Summary for Msd Intl
International Patents:211
US Patents:2
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Msd Intl

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-003 Jul 23, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-004 Jul 23, 2004 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Msd Intl Gmbh ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 AB RX Yes Yes 7,030,106*PED ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Msd Intl

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-003 Jul 23, 2004 RE42461*PED ➤ Try a Free Trial
Msd Intl Gmbh ZETIA ezetimibe TABLET;ORAL 021445-001 Oct 25, 2002 RE42461*PED ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 4,444,784 ➤ Try a Free Trial
Msd Intl VYTORIN ezetimibe; simvastatin TABLET;ORAL 021687-002 Jul 23, 2004 5,846,966*PED ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MSD INTL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg ➤ Subscribe 2009-07-27
➤ Subscribe Tablets 10 mg ➤ Subscribe 2006-10-25

Non-Orange Book US Patents for Msd Intl

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,982,251 Substituted 2-azetidinones useful as hypocholesterolemic agents ➤ Try a Free Trial
7,056,906 Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women ➤ Try a Free Trial
7,071,181 Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors ➤ Try a Free Trial
7,053,080 Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for Msd Intl Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
544 Luxembourg ➤ Try a Free Trial PRODUCT NAME: EZETIMIBE EN COMBINAISON AVEC ROSUVASTATINE OU LEURS SELS PHARMACEUTIQUEMENT ACCEPTEES, Y COMPRIS ROSUVASTATINE SOUD FORME DE SEL DE ZINC; FIRST REGISTRATION DATE: 20140724
C0028 France ➤ Try a Free Trial PRODUCT NAME: EZETIMIBE; NAT. REGISTRATION NO/DATE: NL28237 20030611; FIRST REGISTRATION: DE - 54486.00.00 A 54489.00.00 20021017
C/GB05/010 United Kingdom ➤ Try a Free Trial PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411
C/GB03/023 United Kingdom ➤ Try a Free Trial PRODUCT NAME: EZETIMIBE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: DE 54486.00.00 20021017; DE 54488.00.00 20021017; DE 54487.00.00 20021017; DE 54489.00.00 20021017; UK PL 19945/0001 20030404; UK PL 19945/0002 20030404
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
Johnson and Johnson
Teva
Cipla
QuintilesIMS
Chubb
Queensland Health
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.